Difference between revisions of "Tremelimumab (Imjudo)"
(Created page with "'''in clinical trials''' ==General information== Class/mechanism: Anti-CTLA-4 antibody. CTLA-4 is a negative regulator of T-cell activation and ipilimumab interferes with th...") |
m |
||
| Line 1: | Line 1: | ||
| − | |||
| − | |||
==General information== | ==General information== | ||
Class/mechanism: Anti-CTLA-4 antibody. CTLA-4 is a negative regulator of T-cell activation and ipilimumab interferes with the ability of CTLA-4 to interact with its ligands CD80/CD86. CTLA-4 blockade results in T-cell activation and proliferation, and it is suspected that its anti-neoplastic activity may be due to T-cell mediated anti-tumor immune responses.<ref>[https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=448620 Tremelimumab (ticilimumab) information at Cancer.gov]</ref><ref>[https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-reports-top-line-result-of-tremelimumab-monotherapy-trial-in-mesothelioma-29022016.html AstraZeneca reports top-line result of tremelimumab monotherapy trial in mesothelioma] (AstraZeneca)</ref> | Class/mechanism: Anti-CTLA-4 antibody. CTLA-4 is a negative regulator of T-cell activation and ipilimumab interferes with the ability of CTLA-4 to interact with its ligands CD80/CD86. CTLA-4 blockade results in T-cell activation and proliferation, and it is suspected that its anti-neoplastic activity may be due to T-cell mediated anti-tumor immune responses.<ref>[https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=448620 Tremelimumab (ticilimumab) information at Cancer.gov]</ref><ref>[https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-reports-top-line-result-of-tremelimumab-monotherapy-trial-in-mesothelioma-29022016.html AstraZeneca reports top-line result of tremelimumab monotherapy trial in mesothelioma] (AstraZeneca)</ref> | ||
| Line 15: | Line 13: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
| + | [[Category:Intravenous medications]] | ||
[[Category:Immunotherapy]] | [[Category:Immunotherapy]] | ||
[[Category:T-cell activators]] | [[Category:T-cell activators]] | ||
Revision as of 13:38, 9 September 2017
General information
Class/mechanism: Anti-CTLA-4 antibody. CTLA-4 is a negative regulator of T-cell activation and ipilimumab interferes with the ability of CTLA-4 to interact with its ligands CD80/CD86. CTLA-4 blockade results in T-cell activation and proliferation, and it is suspected that its anti-neoplastic activity may be due to T-cell mediated anti-tumor immune responses.[1][2]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Also known as
CP-675,206